Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Technology isn’t the biggest challenge. Culture is. by Tim Fountaine, Brian McCarthy and Tamim Saleh Artificial intelligence is reshaping business—though not at the blistering pace many assume. True, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results